Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$18.44 USD
+0.20 (1.10%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.44 USD
+0.20 (1.10%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 0% and 26.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
by Zacks Equity Research
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
by Zacks Equity Research
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
by Zacks Equity Research
Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.